NCT00479518

Brief Summary

Patients with stroke or transient ischemic attack (TIA) are at high risk of poor outcome, recurrence of cardiovascular events or vascular death.Until now, no reliable predictive biological marker could be identified in the acute phase of stroke.We hypothese that, in the acute phase of ischemic stroke or TIA, the increase of cardiac ( brain natriuretic peptide, BNP) or renal markers (albuminuria, cystatin C)might predict recurrence of cardiovascular events or vascular death. We want to assess which one of these markers has the best prognosis value , in a prospective study of 300 stroke patients followed during 3 years.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
159

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2007

Longer than P75 for all trials

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2007

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 25, 2007

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 28, 2007

Completed
6.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2014

Completed
2.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2017

Completed
Last Updated

February 27, 2017

Status Verified

February 1, 2017

Enrollment Period

7.1 years

First QC Date

May 25, 2007

Last Update Submit

February 23, 2017

Conditions

Ischemic StrokeTransient Ischemic Attack

Keywords

stroketransient ischemic attackalbuminuriaBNPCystatin C

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with Ischemic stroke or TIA

You may qualify if:

  • Ischemic stroke or TIA in the first 48 hours following the onset of symptoms

You may not qualify if:

  • Patient unable to give an informed consent
  • Urinary sample impossible to collect

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Service de Neurologie / Hopital LAENNEC

Nantes, 44093, France

Location

Service de neurologie / CHU Pontchaillou

Rennes, 35033, France

Location

Service de Neurologie / CHRU de Tours

Tours, 37044, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood Urine

MeSH Terms

Conditions

Ischemic StrokeIschemic Attack, TransientStrokeAlbuminuria

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesBrain IschemiaProteinuriaUrination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • BONNAUD Isabelle, MD

    Service de Neurologie / CHRU de Tours

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 25, 2007

First Posted

May 28, 2007

Study Start

March 1, 2007

Primary Completion

April 1, 2014

Study Completion

February 1, 2017

Last Updated

February 27, 2017

Record last verified: 2017-02

Locations

FR(3)